Back to search results

Contingency Management for Methamphetamine Use in Trauma Patients

This study is looking at a behavioral approach called Contingency Management (CM) to help trauma patients who use methamphetamine. CM involves giving positive rewards, like prizes, when a urine test shows no methamphetamine. The study wants to see how well this program works for patients in Hawaii during their hospital stay and after they go home. Researchers will also ask participants about their experiences with the program. You might be able to join if you are an adult trauma patient, test positive for methamphetamine during your hospital stay, and have used methamphetamine regularly for at least six months. The study aims to enroll 20 participants, but its current status is unclear.

Study design
This is an interventional study with an enrollment goal of 20 participants. It is not specified if it's randomized or blinded.
What's involved
Participants will have urine samples tested for methamphetamine. If negative, they will receive incentives. They will also complete assessments at 6 and 12 weeks after joining the study and may participate in qualitative interviews.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for 12 weeks after enrollment to assess treatment effectiveness.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06931197

Implementing a Contingency Management Program Addressing Methamphetamine Use for and With the People of Hawai'i

Withdrawn
NAAges 18+InterventionalTreatment
Queen's Medical Center
Updated 2026-09-18 on ClinicalTrials.gov
What's tested:Contingency management

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Treatment Effectiveness Assessments (TEA) at 6- and 12-weeks post-enrollment
Measured over From enrollment to 6 and 12 weeks

Conditions

Contingency Management
Methamphetamine Use Disorder

Explore related trials

Amphetamine-induced organic mental disorder

NCT06931197

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • The Queen's Medical Center

    Honolulu, Hawaiino site contact published

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Admitted trauma patients
Age greater than 18 years old
Urine drug screen positive for methamphetamines during the current hospitalization
Report at least weekly methamphetamine use
First methamphetamine use greater than 6 months prior to injury
Report at least 4 Diagnostic and Statistical Manual of Mental Disorders 5th Edition, Amphetamine-Type Substance Use Disorder symptoms (at least moderate disease)
Glasgow Coma Scale ≥13 upon arrival to the emergency department
Ability to understand and participate in study procedures
Ability to communicate in English
Expected discharge date within 45 days on the day of screening / recruitment

Exclusion

Active psychosis (reporting auditory or visual hallucinations)
Under ongoing cardiorespiratory monitoring
Evidence of moderate or severe traumatic brain injury
Patients who are known to be pregnant
Prisoners
Individuals incarcerated at the time of their hospitalization
Individuals lacking capacity to provide, or are otherwise unable or unwilling to provide written informed consent

What this trial measures

  • Treatment Effectiveness Assessments (TEA) at 6- and 12-weeks post-enrollmentFrom enrollment to 6 and 12 weeks

    TEA (Treatment Effectiveness Assessment) at 6- and 12-weeks post-enrollment to assess both patient-reported medium-term program effectiveness. TEA asks individuals to respond to changes in four domains following a drug treatment program: Substance use, health, lifestyle, and community. The score for each domain can range from 1 (no change or not much) to 10 (much better), for total score of 4-40. This score allows for the prioritization of each participants values, and therefore does not require strict abstinence to demonstrate benefit from drug treatment.